Article thumbnail

The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist

By Ayse Seyhan and Baris Ata

Abstract

Corifollitropin alfa is a synthetic recombinant follicle-stimulating hormone (rFSH) molecule containing a hybrid beta subunit, which provides a plasma half-life of ∼65 hours while maintaining its pharmocodynamic activity. A single injection of corifollitropin alfa can replace daily FSH injections for the first week of ovarian stimulation for in vitro fertilization. Stimulation can be continued with daily FSH injections if the need arises. To date, more than 2500 anticipated normoresponder women have participated in clinical trials with corifollitropin alfa. It is noteworthy that one-third of women did not require additional gonadotropin injections and reached human chorionic gonadotropin criterion on day 8. The optimal corifollitropin dose has been calculated to be 100 μg for women with a body weight ≤60 kg and 150 μg for women with a body weight >60 kg, respectively. Combination of corifollitropin with daily gonadotropin-releasing hormone antagonist injections starting on stimulation day 5 seems to yield similar or significantly higher numbers of oocytes and good quality embryos, as well as similar ongoing pregnancy rates compared with women stimulated with daily rFSH injections. Stimulation characteristics, embryology, and clinical outcomes seem consistent with repeated corifollitropin-stimulated assisted reproductive technologies cycles. Multiple pregnancy or ovarian hyperstimulation syndrome rates with corifollitropin were not increased over daily FSH regimen. The corifollitropin alfa molecule does not seem to be immunogenic and does not induce neutralizing antibody formation. Drug hypersensitivity and injection-site reactions are not increased. Incidence and nature of adverse events and serious adverse events are similar to daily FSH injections. Current trials do not provide information regarding use of corifollitropin alfa in anticipated hyper- and poor responders to gonadotropin stimulation. Although corifollitropin alfa is unlikely to be teratogenic, at the moment data on congenital malformations is missing

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3163654
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2000). A dose proportionality study of subcutaneously and intramuscularly administered recombinant human follicle-stimulating hormone (Follistim*/Puregon) in healthy female volunteers. Fertil Steril.
  2. (2009). A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reprod.
  3. (2009). Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Human Reprod Update.
  4. (2002). An international survey of the health economics of IVF and ICSI. Hum Reprod Update.
  5. Assay of the follicle stimulating hormone based on the augmentation with human chorionic gonadotropin.
  6. (1999). Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon) by Pen-injector and syringe. Hum Reprod.
  7. (1999). Biological characterization of recombinant human follicle stimulating hormone isoforms. Hum Reprod.
  8. (1996). Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy. Hum Reprod Update.
  9. Cumulative conception and livebirth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin.
  10. Cumulative conception and livebirth rates after in-vitro fertilisation.
  11. (1992). Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit.
  12. DiStefano JJ 3rd. Metabolism of exogenous human chorionic gonadotrophin in men.
  13. (2010). Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clin Pharmacol Ther.
  14. (2001). Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril.
  15. Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone agonists with extended carboxyl-terminal peptides.
  16. (1965). Fecundity and infertility in the United States,
  17. (2001). First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. Human Reprod.
  18. First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSHCTP) for in vitro fertilization.
  19. (2006). GnRHantagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online.
  20. (2011). Gonadotrophinreleasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev.
  21. Gurpide E, Vande Wiele RL. Metabolism of HCG in man.
  22. (2001). Human FSH isoforms: carbohydrate complexity as determinant of in-vitro bioactivity. Mol Cell Endocrinol.
  23. Human pituitary follicle-stimulating hormone: distribution, plasma clearance and urinary excretion as determined by radioimmunoassay.
  24. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
  25. Induction of multiple follicular development by a single dose of longacting recombinant follicle-stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
  26. Long-acting follicle-stimulating hormone analogs containing N-linked glycosylation exhibited increased bioactivity compared with o-linked analogs in female rats.
  27. Metabolic clearance and production rates of human luteinizing hormone in pre- and postmenopausal women.
  28. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility.
  29. (2010). Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reprod Biomed Online.
  30. Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant.
  31. (1983). Pituitary follicle-stimulating hormone heterogeneity: assessment of biologic activities of each follicle-stimulating hormone form. Fertil Steril.
  32. Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Hum Reprod.
  33. (2002). Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Human Reprod.
  34. Structure and location of the O-glycosidic carbohydrate units of human chorionic gonadotropin.
  35. The biological role of the carboxyl-terminal extension of human chorionic gonadotropin [corrected] beta-subunit.
  36. (2008). The Corifollitropin Alfa Dose-finding Study Group. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reprod.
  37. The Corifollitropin Alfa Ensure study group. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women.
  38. The glycoprotein hormones: recent studies of structure-function relationships.
  39. (1993). The psychological impact of infertility: a comparison with patients with other medical conditions. J Psychosom Obstet Gynaecol.
  40. (1992). The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril.
  41. (2004). Why do couples discontinue in vitro fertilization treatment? A cohort study. Fertil Steril.
  42. (2008). Why do couples dropout from IVF treatment? A prospective cohort study. Hum Reprod.